{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Conditions%2C+Multiple&page=45", "query": { "condition": "Chronic Conditions, Multiple", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 1198, "total_pages": 120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Conditions%2C+Multiple&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Conditions%2C+Multiple&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T01:41:33.912Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01977573", "title": "A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "GSK1278863", "type": "DRUG" }, { "name": "rhEPO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 252, "start_date": "2013-10-31", "completion_date": "2015-06-15", "has_results": true, "last_update_posted_date": "2018-10-12", "last_synced_at": "2026-10-29T01:41:33.912Z", "location_count": 25, "location_summary": "Peoria, Arizona • Azusa, California • La Mesa, California + 21 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Azusa", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01977573" }, { "nct_id": "NCT01879410", "title": "A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI", "type": "DRUG" }, { "name": "FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS", "type": "DRUG" }, { "name": "Placebo DISKUS", "type": "DRUG" }, { "name": "Placebo NDPI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 700, "start_date": "2013-06-13", "completion_date": "2014-01-09", "has_results": true, "last_update_posted_date": "2017-11-08", "last_synced_at": "2026-10-29T01:41:33.912Z", "location_count": 15, "location_summary": "Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Coeur d'Alene", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01879410" }, { "nct_id": "NCT00592046", "title": "A Phase I Trial of ZIO-101 in Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemia", "Chronic Myeloproliferative Disease", "Chronic Lymphoproliferative Disease", "Multiple Myeloma", "Lymphoma", "Poor-risk Myelodysplasia (MDS)" ], "interventions": [ { "name": "ZIO-101 (Darinaparsin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2005-05", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2012-07-19", "last_synced_at": "2026-10-29T01:41:33.912Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00592046" }, { "nct_id": "NCT00725062", "title": "Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "CD4+CD25+ regulatory T cells", "type": "BIOLOGICAL" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 3, "start_date": "2008-06", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-10-29T01:41:33.912Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00725062" }, { "nct_id": "NCT03034915", "title": "A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "UMEC/VI 62.5/25 mcg via ELLIPTA", "type": "DRUG" }, { "name": "UMEC 62.5 mcg via ELLIPTA", "type": "DRUG" }, { "name": "Salmeterol 50 mcg via DISKUS", "type": "DRUG" }, { "name": "Placebo via ELLIPTA", "type": "DRUG" }, { "name": "Placebo via DISKUS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 2696, "start_date": "2017-06-16", "completion_date": "2018-06-18", "has_results": true, "last_update_posted_date": "2020-03-11", "last_synced_at": "2026-10-29T01:41:33.912Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Lincoln, California • Clearwater, Florida + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lincoln", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03034915" }, { "nct_id": "NCT02290951", "title": "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Odronextamab multiple dose levels", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2015-01-09", "completion_date": "2025-08-21", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-10-29T01:41:33.912Z", "location_count": 10, "location_summary": "Orange, California • Stanford, California • Tampa, Florida + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02290951" }, { "nct_id": "NCT04282343", "title": "DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Plasma Cell Myeloma" ], "interventions": [ { "name": "The DISCO App", "type": "BEHAVIORAL" }, { "name": "Usual Care", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-02-25", "completion_date": "2022-10-21", "has_results": false, "last_update_posted_date": "2023-05-03", "last_synced_at": "2026-10-29T01:41:33.912Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04282343" }, { "nct_id": "NCT04210843", "title": "Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Ligelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1033, "start_date": "2020-04-08", "completion_date": "2022-09-01", "has_results": true, "last_update_posted_date": "2024-06-20", "last_synced_at": "2026-10-29T01:41:33.912Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04210843" }, { "nct_id": "NCT04312685", "title": "Transitioning to a Valve -Gated Intrathecal Drug Delivery System", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pain", "Pain, Chronic", "Pain, Intractable", "Pain, Back" ], "interventions": [ { "name": "Prometra II Programmable Pump system - Flowonix Medical", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Bux, Anjum, MD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 120, "start_date": "2020-07-27", "completion_date": "2023-11-30", "has_results": false, "last_update_posted_date": "2021-07-07", "last_synced_at": "2026-10-29T01:41:33.912Z", "location_count": 8, "location_summary": "Idaho Falls, Idaho • Overland Park, Kansas • Lexington, Kentucky + 5 more", "locations": [ { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Slidell", "state": "Louisiana" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04312685" }, { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-29T01:41:33.912Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" } ] }